Table 1 Clinical and immunological characteristics of APS patients, "aPL carriers", and CTR patients

Total patients

18

24

18

Female–male sex

13–5

23–1

8–10

Age (years, mean ± SD)

50 ± 13.8

46.4 ± 16.4

74 ± 12.5

Disease duration (years, mean ± SD)

7.6 ± 7.7

–

–

Primary–secondary forms

12–6

17–7

–

Arterial/venous thrombosis

16/18 (88.9)

–

9 (50.0)

Pregnancy morbidity

3/13 (23.1)

–

–

Atrial fibrillation

–

–

6 (33.3)

Mechanical heart valves

–

–

3 (16.7)

Arterial hypertension

6

8

6

Diabetes mellitus

0

1

2

LAC positivity

5/18 (27.8)

5/24 (20.8)

–

ACL IgG positivity

4/18 (22.2)

9/24 (37.5)

–

ACL IgM positivity

9/18 (50.0)

5/24 (20.8)

–

Anti-b2GPI IgG positivity

5/18 (27.8)

8/24 (33.3)

–

Anti-b2GPI IgM positivity

8/18 (44.4)

12/24 (50.0)

–

Single positivity^a

10/18 (55.5)

13/24 (54.1)

–

Double positivity^b

5/18 (27.8)

10/24 (41.7)

–

Triple positivity^c

3/18 (16.7)

1/24 (4.2)

–